Skip to main content
Equibles
RGNX logo

RGNX · REGENXBIO Inc.

Track RGNX — free

Use RGNX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RGNX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.77 +0.11 (+0.98%) At close · Aug 14
Market Cap
$720.20M
Shares
66.01M

REGENXBIO Inc. Earnings Call Transcripts

Every quarterly earnings call for REGENXBIO Inc. (RGNX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼13.8% $26.51M −$75.48M '22 Q3 22-11-03 ▼92.1% $31.34M −$59.94M '22 Q4 23-02-28 ▼13.9% $19.14M −$66.68M '23 Q1 23-05-03 ▼38.8% $19.98M −$72.06M '23 Q2 23-08-02 ▲9.1% $28.91M −$61.87M '23 Q3 23-11-08 ▼29.1% $22.21M −$62.89M '23 Q4 24-02-27 ▼18.4% $15.62M −$63.33M '24 Q1 24-05-08 ▲11.6% $22.30M −$52.99M '24 Q2 24-08-01 ▼16.3% $24.20M −$59.60M '24 Q3 24-11-06 ▼4.5% $21.21M −$51.19M '24 Q4 25-03-13 ▲469.8% $89.01M $6.08M '25 Q1 25-05-12 ▼4.2% $21.36M −$70.87M '25 Q2 25-08-07 ▲22.9% $29.73M −$61.94M '25 Q3 25-11-06 ▲43% $30.34M −$67.15M '25 Q4 26-03-05 ▼92.8% $6.39M −$90.05M '26 Q1 26-05-14 LATEST ▲405.7% $108.02M $22.71M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
REGENXBIO Inc. Q2 FY2026 Earnings Call
Revenue
$108.02M
▲ 405.7% YoY
Diluted EPS
$0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
REGENXBIO Inc. Q1 FY2026 Earnings Call
Confident tone RGX-202 pivotal Phase III data Microdystrophin expression and functional correlation Approval pathway and regulatory strategy
Revenue
$6.39M
▼ 92.8% YoY
Diluted EPS
$-1.72
▼ 1533.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
REGENXBIO Inc. Q4 FY2025 Earnings Call
Positive tone RGX202 Duchenne gene therapy AbbVie partnership and Navigate in diabetic retinopathy Regulatory pathway and FDA engagement
Revenue
$30.34M*
▲ 43% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
REGENXBIO Inc. Q3 FY2025 Earnings Call
Confident tone RGX-202 Duchenne pivotal trial and BLA Subretinal sura-vec for wet AMD (AbbVie) RGX-121 MPS II BLA and approval
Revenue
$29.73M
▲ 22.9% YoY
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
REGENXBIO Inc. Q2 FY2025 Earnings Call
Revenue
$21.36M
▼ 4.2% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
REGENXBIO Inc. Q1 FY2025 Earnings Call
Confident tone RGX-202 Duchenne Pivotal Program Retinal Programs / ABBV-RGX-314 Partnership RGX-121 / Hunter Syndrome Regulatory Progress
Revenue
$89.01M
▲ 469.8% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
REGENXBIO Inc. Q4 FY2024 Earnings Call
Confident tone RGX-202 Duchenne muscular dystrophy pivotal program Regulatory milestones and FDA interactions Clinical data readouts (biomarker and functional)
Revenue
$21.21M*
▼ 4.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
REGENXBIO Inc. Q3 FY2024 Earnings Call
Confident tone RGX-202 Duchenne program RGX-314 retinal franchise with AbbVie RGX-121 MPS II / Hunter syndrome BLA
Revenue
$24.20M
▼ 16.3% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
REGENXBIO Inc. Q2 FY2024 Earnings Call
Confident tone AbbVie RGX-314 retinal programs RGX-202 Duchenne gene therapy Fellow Eye study and immune response
Revenue
$22.30M
▲ 11.6% YoY
Diluted EPS
$-1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
REGENXBIO Inc. Q1 FY2024 Earnings Call
Confident tone RGX-202 Duchenne program and pivotal dose Diabetic retinopathy suprachoroidal pivotal plans RGX-314 AbbVie collaboration
Revenue
$15.62M
▼ 18.4% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
REGENXBIO Inc. Q4 FY2023 Earnings Call
Confident tone RGX-202 Duchenne Program AbbVie Partnership Milestones RGX-121 / MPS II (Hunter Syndrome)
Revenue
$22.21M*
▼ 29.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
REGENXBIO Inc. Q3 FY2023 Earnings Call
Revenue
$28.91M
▲ 9.1% YoY
Diluted EPS
$-1.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
REGENXBIO Inc. Q2 FY2023 Earnings Call
Revenue
$19.98M
▼ 38.8% YoY
Diluted EPS
$-1.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
REGENXBIO Inc. Q1 FY2023 Earnings Call
Revenue
$19.14M
▼ 13.9% YoY
Diluted EPS
$-1.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
REGENXBIO Inc. Q4 FY2022 Earnings Call
Revenue
$31.34M*
▼ 92.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
REGENXBIO Inc. Q3 FY2022 Earnings Call
Revenue
$26.51M
▼ 13.8% YoY
Diluted EPS
$-1.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
REGENXBIO Inc. Q2 FY2022 Earnings Call
Revenue
$32.65M
▲ 48.2% YoY
Diluted EPS
$-1.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
REGENXBIO Inc. Q1 FY2022 Earnings Call
Revenue
$22.22M
▲ 17.7% YoY
Diluted EPS
$-1.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
REGENXBIO Inc. Q4 FY2021 Earnings Call
Revenue
$398.65M*
▲ 1759% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
REGENXBIO Inc. Q3 FY2021 Earnings Call
Revenue
$30.77M
▼ 68.9% YoY
Diluted EPS
$-1.37
▼ 695.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
REGENXBIO Inc. Q2 FY2021 Earnings Call
Revenue
$22.04M
▲ 33% YoY
Diluted EPS
$-1.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
REGENXBIO Inc. Q1 FY2021 Earnings Call
Revenue
$18.88M
▲ 7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-05
REGENXBIO Inc. Q4 FY2020 Earnings Call
Revenue
$21.45M
▲ 82.2% YoY
Diluted EPS
$-1.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
REGENXBIO Inc. Q3 FY2020 Earnings Call
Revenue
$98.91M
▲ 572.9% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
REGENXBIO Inc. Q2 FY2020 Earnings Call
Revenue
$16.57M
▲ 110.2% YoY
Diluted EPS
$-0.91
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
REGENXBIO Inc. Q1 FY2020 Earnings Call
Revenue
$17.64M
▲ 1895.9% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 167 filings 161 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)